Nanopublications LDF server

Matches in Nanopublications for { <http://purl.org/np/RApy55xPrl6WgXAMrLv-p6fqzpIZsTtxr8jws8NHdAg90#association> ?p ?o ?g. }

• association type Statement assertion.
• association label "quinapril tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with quinapril tablets usp control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy quinapril tablets usp may be used alone or in combination with thiazide diuretics heart failure quinapril tablets usp is indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and or digitalis in using quinapril tablets usp consideration should be given to the fact that another ace inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril tablets usp does not have a similar risk see warnings black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non blacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks" assertion.
• association object DOID_10763 assertion.
• association predicate treats assertion.
• association subject drugbank:DB14217 assertion.
• association relation TreatmentIndication assertion.
• association provided_by NeuroDKG assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.